Case Study

Satisfying Aggressive Timelines With A Simplified Supply Chain For Drug Delivery

Source: Thermo Fisher Scientific
Pharma Manager Blockchain supply chain 450x300

The new business model of the biopharmaceutical industry that focuses on the unmet needs of smaller patient populations has diversified today’s pipelines and brought new hope to patient care. In its own pursuit to improve the quality of life for patients in need, Kaleido Biosciences, a clinical-stage healthcare company, has focused its efforts on Microbiome Metabolic Therapies (MMT™) to help address a variety of diseases and conditions. Their lead candidate, KB195, is intended to treat urea cycle disorder (UCD), which affects a small population of patients who inherit this serious, rare, and life-threatening disease.1 To bring KB195 to patients, Kaleido needed an IND filed by the end of its first year. And as a small company, it lacked the resources to accomplish this on its own, so it had to consider an alternative yet efficient route to meet its aggressive timeline.

To meet an aggressive timeline with a lack of resources, Kaleido Biosciences had to consider an alternative yet efficient route.

VIEW THE CASE STUDY!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: